The scientific discussion meeting was divided into three sessions. The agenda of the first session was “Current and Future Treatment System of Follicular Lymphoma (FL)”. Dr. A.J.M. Saleh, Consultant and Coordinator, Adult Hematology/HSCT, Apollo Hospital Bangladesh was present as a speaker on the occasion. Prof. Dr. Alamgir Kabir, Head of Department, Dhaka Medical College Hospital, Prof. Dr. M. A. Aziz, Chairperson, Department of Hematology, BSMMU, Col. Dr. Mohammad Mosleh Uddin were present as panel members of this session. The doctors who were present were informed about the current treatment system of Follicular Lymphoma and the new aspect of Follicular Lymphoma treatment system using “Obinutuzumab” innovated by Roche, approved by the Directorate General of Drug Administration in Bangladesh. The clinical trial that was conducted before the approval of this medicine and its results were the topics discussed here. The effectiveness of the medicine in the patient's body and possible side effects are discussed.
In his opening speech, General Secretary of Hematology Society of Bangladesh, Prof. Dr. M.A. Aziz, Chairperson, Department of Hematology, BSMMU said, “Such an event on haematology will undoubtedly benefit the patients of Bangladesh, by introducing the latest research findings, new innovations and best practices among the experts of different countries our capacity will increase.” Major General Susane Giti, Armed Forces Institution of Pathology said, “As the number of patients with blood disorders is increasing, we need to increase our capacity equally and increase the number of modern diagnostic equipments.” Prof. Dr. M. A. Khan, former Head of the Department, Department of Hematology, Dhaka Medical College Hospital said, "We are serving patients from the Bone Marrow Transplant (BMT) Unit of Dhaka Medical College for blood cancer treatment, but in this case, it is necessary to increase the allocation and increase the capacity”.
The agenda of the next session was the medical care requirements of “Diffuse Large B-cell Lymphoma (DLBCL)” and its future treatment solutions. The speaker of this session was Prof. Dr. Md. Mahabubur Rahman, Head, Department of Hematology, National Institute of Cancer Research and Hospital (NICRH). Prof. Dr. A. B. M. Yunus, former Chairperson, Department of Hematology, BSMMU, Brigadier General Dr. Farooq Ahmed, Square Hospital, and Prof. Dr. M. A. Khan, former Head of the Department, Department of Hematology, Dhaka Medical College Hospital were present as panel members of this session.
The agenda of the third and final session was the challenges of treatment system of Hemophilia A. The speaker of this session was Dr. Akhil Ranjan Biswas, Associate Professor, Department of Hematology, Dhaka Medical College Hospital. Major General Susane Giti, Armed Forces Institution of Pathology, Prof. Dr. Salma Afroz, Birdem Hospital, Dr. Amin Lutful Kabir, Associate Professor, Department of Hematology, BSMMU were present as panel members of this session.
The inauguratory speech was delivered by the General Secretary of Hematology Society of Bangladesh, Professor Dr. M. A. Aziz, Chairperson, Department of Hematology, BSMMU and concluded by the President of Hematology Society of Bangladesh, Professor Dr. Md. Mahabubur Rahman, Head of the Department, Department of Hematology, National Institute of Cancer Research and Hospital. Prof. Dr. Md. Mahabubur Rahman in his speech thanked Roche Bangladesh for organizing such a scientific discussion meeting and urged the doctors specializing in all blood diseases to be aware of the new treatment system and provide medical care to the patients accordingly. He also said, "All those involved in medical care should work together for the welfare of patients. The desired results can be achieved only through proper coordination and prioritizing the needs of the patients and the private sector should also take initiative in this regard. Such programs of Roche should be continued on a regular basis.”
On behalf of Roche Bangladesh, assurances were given to continue such scientific discussions and initiatives related to patient welfare. The program ended at 10 pm.
This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.